DW-224a is a fluoroquinolone antibiotic with the formula {1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro [3, 4] oct-6-yl]-4-oxo-1,4-dihydro [1, 8] naphthyridine-3-carboxylic acid hydrochloride}, a new group of drugs recently developed by the Research Laboratory of Dong Wha Pharmaceutical Industry Co. (Anyang, Republic of Korea), employed for the treatment of both gram-positive and gramnegative bacterial infections.
4-week study) immediately after oral administration, a 1-ml aliquot of blood sample was collected via the cephalic vein into a heparinized tube at 0, 0.5, 1.5, 3, 6, 10, and 24 h after dosing. Blood samples were centrifuged immediately and a 200-ml aliquot of plasma sample was stored in a Ϫ20°C freezer (Micom CRF-1043D, Samsung Company, Seoul, Republic of Korea) until HPLC analysis of DW-224a.
Selection of Doses In a previous 7-d repeated oral dose toxicity study (unpublished data), vomiting and salivation were observed in dogs at doses higher than 50 mg/kg/d in both sexes and atrophy and seminiferous tubules in testes were observed in males at 100 mg/kg/d. Therefore a dose of 90 mg/kg/d was selected for the highest dose in this study. Doses of 30 and 10 mg/kg/d were selected as middle and low doses, respectively, using a common ratio of 3. The therapeutic range (Css) of DW-224a is estimated to be 1-2 mg/ml.
Subacute Toxicity During and/or at the end (on the 29th day) of 4-week oral administration, the followings were checked and measured carefully. 1) Mortality and clinical observations were performed daily for clinical signs of toxicity and mortality. 2) Body weight gain was measured weekly. 3) Food intake was recorded weekly. 4) Ocular fundus examination, slit lamp examination, and macroscopic observations were carried out in the preadministration phase and the last week of the treatment period. The conjunctiva, sclera, cornea, lens, and iris of each eye were also examined. 5) Urinalysis was carried out in the preadministration phase and the last week of the treatment period for items including glucose, pH, specific gravity, protein, bilirubin, ketone, occult blood and sediment, nitrite, urobilinogen and 24-h urine volume. 6) Hematologic examination was performed in the preadministration phase and the last week of the treatment period for the items such as white blood cell (WBC) count, red blood cell count, hemoglobin concentration, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration (MCHC), platelets, differential leukocyte count, reticulocyte count, and prothrombin time. 7) Biochemical examination was carried out in the preadministration phase and the last week of the treatment period for the items including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, glucose, total protein, albumin, albumin/globulin ratio, urea nitrogen, creatinine, triglyceride, total cholesterol, total bilirubin, calcium, phospholipid, creatine phosphokinase, chloride, sodium, and potassium. 8) Electrocardiographic examination was carried out in the pretreatment phase and the 2nd and 4th weeks of the treatment period. Standard limb leads (I, II, and III) and augmented unipolar limb leads (aV R , aV L , and aV F ) were adopted. 9) Gross findings were recorded at necropsy carried out the day after the last day of treatment. 10) Organ weights of the brain, hypophysis, heart, liver, spleen, kidneys, adrenal glands, prostate, testes, and ovaries were measured. 11) Microscopic findings were recorded, including the brain, hypophysis, thyroid (including the parathyroid), lung (including the bronchi), trachea, heart, thymus, liver, gall bladder, kidneys, pancreas, spleen, adrenal glands, testes, prostate, epididymides, ovaries, uterus, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, femur, skeletal muscle, mesenteric lymph nodes, submaxillary lymph nodes, aorta, eyes, sciatic nerve, skin and subcutis, mammary glands, sternum, tongue, vagina, salivary glands (submanibular), abnormal lesions, thoracic spinal cord, urinary bladder, and ears (for identification only). All results were compared with those of the control group.
HPLC Analysis of DW-224a
The concentrations of DW-224a in the above plasma samples were analyzed using the HPLC method using a deproteinization procedure. A triple volume of acetonitrile was added to plasma samples and after vortex-centrifugation at 15000 rpm for 1 min, a 100-ml aliquot of the supernatant was removed and dried of all solvent using vacuum concentration system (Spinvac, Hanil Electronics Co., Seoul, Republic of Korea). After reconstitution with 50 ml of acetonitrile, a 5-ml aliquot was injected directly into a microbore C 18 column (Capcell-Pak, 5-mm, 2.0ϫ250 mm i.d., Shiseido, Tokyo, Japan). In the mobile phase, acetonitrile : methanol (MeOH) : phosphate buffer (pH 2.5) : 1 M tetrabutylammonium dihydrogen phosphate (TBA) (185 : 85 : 720 : 10, v/v/v/v) was run at a flow rate of 0.25 ml/min and the column effluent was monitored with a UV detector set at 275 nm. The retention time and detection limit of DW-224a in dog plasma were approximately 9 min and 20 ng/ml ( Fig. 1) , respectively. The coefficients of variation for the response factor (peak height of DW-224a, cm/concentration of DW-224a, mg/ml) in dog plasma were less than 3.0% in the concentration range from 0.1 to 10 mg/ml. The relative recovery (compared to response factor in distilled water) of DW-224a in dog plasma was 104Ϯ8.05 in the concentration range from 0.1 to 10 mg/ml.
Pharmacokinetic Analysis The area under the plasma concentration-time curve from time 0 to the last measured time, 24 h, in plasma (AUC 0-24 h ) was calculated by the trapezoidal rule method employing the logarithmic trapezoidal rule 7) for the calculation of the area during the declining plasma-level phase and the linear trapezoidal rule during the rising-level phase. The maximum plasma concentration (C max ) and the time of C max (T max ) were obtained directly from the experimental data. The detector sensitivity was set at 0.02 AUFS and recorder sensitivity was set atStatistical Analysis A p value of Ͻ0.05 was considered to be statistically significant using the t-test between the two means for paired or unpaired data or Duncan's multiple range test of SPSS posteriori analysis of variance (ANOVA) program among the means for unpaired data. The results are expressed as meanϮS.D.
RESULTS AND DISCUSSION
Subacute Toxicity A summary of subacute toxicity of DW-224a during and/or after 4-week oral administration of the drug at doses of 10, 30, and 90 mg/kg/d is listed in Table  1 . Death was not observed at any dose studied, including control dogs. Vomiting and salivation were found in high frequencies in both male and female dogs at 30 mg/kg/d and 90 mg/kg/d, but in low frequencies at 10 mg/kg/d. Anorexia was observed in both male and female dogs at 90 mg/kg/d with high frequency. The male dogs at the 90 mg/kg/d dose showed a tendency to decrease in body weight gain on the 20th (9206Ϯ608 versus 9946Ϯ319 g) and 28th (9148Ϯ360 versus 10099Ϯ381 g) days compared with the control dogs (body weights on day 0 were 10140Ϯ1920 and 9633Ϯ259 g for 90 mg/kg/d dogs and control dogs, respectively). The female dogs at the 90 mg/kg/d dose showed a tendency to decrease in body weight gain on the 21st (8742Ϯ245 versus 8843Ϯ726 g) and 28th (8057Ϯ585 versus 8862Ϯ685 g) days compared with control dogs (body weights on day 0 were 8793Ϯ445 and 8542Ϯ561 g for 90 mg/kg dogs and control dogs, respectively). Both male (100Ϯ173.2 versus 300Ϯ0 g) and female (73.0Ϯ64.1 versus 293Ϯ12.7 g) dogs at the dose of 90 mg/kg/d showed a tendency to decrease in food intake on the 21st day. (The food intake on day 0 was 300Ϯ0 g). No treatment-related ophthalmic, urinary (Table 2) , or hematologic (Table 3 ) changes were observed in any dog of either sex.
In both male and female dogs, a significant increase in serum total cholesterol level at 30 mg/kg/d (441Ϯ89.3 versus 176Ϯ11.0 for male dogs and 496Ϯ29.7 versus 180Ϯ30.1 for female dogs) and at 90 mg/kg/d (373Ϯ55.5 for male dogs and 515Ϯ71.3 for female dogs) was observed in week 4 of administration compared with control dog (Table 4 ). In female dogs in week 4 of administration at 30 mg/kg/d and at 90 mg/kg/d, the serum phospholipid level (626Ϯ18.2 and 585Ϯ91.5 versus 385Ϯ44.9) was significantly higher compared with control dogs.
Electrocardiography data showed a trend toward increased in QT interval in both male and female dogs at 90 mg/kg/d compared with control dogs (Table 5 In male dogs at 90 mg/kg/d, atrophy of testes was found in A tendency to decrease in both male and female dogs Ophthalmic findings -
Significant increase in the numbers of -
both columnar cells and WBC in male dogs Hematology -
Significant increase in serum levels of Significant increase in serum levels of total cholesterol in both sexes. total cholesterol in both sexes. Significant increase in serum levels of Significant increase in serum levels of phospholipid in female dogs phospholipid in female dogs Electrocardiography -
A tendency to increase QT interval in both sexes Gross findings -
Atrophy of testes and prostate in male dogs Organ weights - two cases (Table 6 ). No gonadal treatment-related changes were observed in female dogs. In female dogs at 90 mg/kg/d, the relative weights (% body weight) of the spleen (0.34Ϯ 0.011 versus 0.25Ϯ0.036) and adrenal glands (0.013Ϯ0.003 versus 0.008Ϯ0.001) were significantly greater than those in control dogs. In male dogs at 10 mg/kg/d, one case of atrophy of the thymus and one case of mineralization of the spleen were observed. In male dogs at 30 mg/kg/d, one case each of pancreatic hyperplasia, atrophy of the testes, oligospermia of the epididymis, and presence of immature germ cells, and two cases of atrophy of the thymus were observed. In male dogs at 90 mg/kg/d, one case each of pancreatic hyperplasia, dilated epicardial lymphatics of the heart, atrophy of the prostate, and aspermia, and three cases of atrophy of the thymus and testes were observed. In female dogs at 10 mg/kg/d, one case of atrophy of the thymus and one case of mineralization of the kidney were observed. In female dogs at 30 mg/kg/d, one case each of mineralization of the kidney, and nephrosis, and three cases of atrophy of the thymus were observed. In female dogs at 90 mg/kg/d, one case of mineralization of the kidney and three cases of atrophy of the thymus were observed.
The present study was conducted to investigate the potential subacute toxicity of DW-224a administered by gavage to beagle dogs at dose levels of 0, 10, 30, and 90 mg/kg/d for 4 weeks. Vomiting is thought to attribute to DW-224a administration based on incidence-dosage relationships. Anorexia resulted in decreased food intake and body weight gain. However, no treatment-related changes were observed in the mortality, urinalysis, and hematology. The significant increase in numbers of both columnar cells and WBC observed in male dogs at the dose of 30 mg/kg/d was not considered to be treatment related effects because they lacked a dose-response relationship and were observed in only one sex. The significant increase in MCHC in males in all dosage groups and the significant decrease in neutrophils in females in the 30 mg/kg/d group were of doubtful toxicological significance since they were very slight and within the limits of the normal biological variation.
8) DW-224a had some effects on the liver in both male and female dogs at 90 mg/kg/d as evidenced by the significantly higher serum total cholesterol and phospholipid level. It is known that trovafloxacin, a fluoroquinolone derivative, causes unpredictable liver failure and this has been reported even with short-term exposure (2 d). 1) In our experiment, although these findings were not associated with gross or microscopic pathological changes, we consider them as adverse effects of the test article treatment. We have not yet determined the mechanism of these findings, and further study is required. These results also agree with the previous reports of Guzman et al. 9) and Kawamura et al. 10) A decrease in aspartate aminotransferase and the creatine phosphokinase levels and an increase in Na were found in females in the 90 mg/kg/d group. However, these changes were within the normal range for dogs and did not exhibit a dose-response relationship.
8) The increasing tendency of the QT interval in both sexes at 90 mg/kg/d could be the result of the histamine release effect of DW-224a. 11, 12) The atrophy of thymus observed in both sexes was found to be atrophy of the cortex caused by a decrease in thymocytes. This showed a dose-response relationship and was considered to be treatment related toxicity. However, both the decrease in cell number and the atrophy of the thymus observed at 10 mg/kg/d were considered reversible changes that would disappear after the recovery period, because slight changes were monitored in only one dog of each sex.
The testicular atrophy observed at both 30 and 90 mg/kg/d was due to the disappearance of spermatocytes and spermatogonia in seminiferous tubules and the atrophy of seminiferous tubules. Although the testicular atrophy was not severe, multinuclear giant cells and vacuolation in Sertoli cells were observed in seminiferous tubules. Quinolone antibiotics such as ofloxacin and ciprofloxacin are known to be toxic to the testis. 1) In particular, ofloxacin was reported to suppress sperm production and induce the atrophy of seminiferous tubules. 13) Considering these reports, the testis appeared to be the target organ of DW-224a, as in the case of other quinolones. The oligospermia and spermatocytes seen in the epididymis were considered to be secondary effects resulting from testicular changes. Some males and females in the negative control and treated groups exhibited abnormal histopathological changes including mineralization and 836
Vol. 26, No. 6 nephrosis of the kidney, mineralization of the spleen, pancreatic hyperplasia, atrophy of the prostate, and dilated epicardial lymphatics of the heart, but there were no obvious differences in the incidence of the histopathological changes among the groups. Based on these results, it was concluded that 4-week re- peated oral dosing with DW-224a resulted in vomiting, salivation, increased serum cholesterol level, and atrophy of the thymus and testes in both sexes at dose levels higher than 30 mg/kg/d. The target organ for DW-224a appears to be the thymus and testes. The absolute toxic dose of DW-224a was considered to be 30 mg/kg/d, and no observed adverse effect level was considered to be 10 mg/kg/d for both male and female dogs. Pharmacokinetics The plasma concentration-time profiles on the 1st and 28th day after oral administration of DW224a at doses of 10, 30, and 90 mg/kg/d to dogs are shown in Fig. 2 , and relevant pharmacokinetic parameters are listed in Table 7 . After oral administration, the absorption of DW224a was fast; the plasma concentration of DW-224a was detected from the first blood sampling time (0.5 h) and reached its peak within 1-3 h. There were no significant differences in pharmacokinetic parameters of DW-224a between male and female dogs after 4-week oral administration for the three different doses, and similar results were also obtained after a single administration. Therefore we combined the pharmacokinetic parameters from male and female dogs (grand mean in Table 2 ). After a single (on the 1st day) oral administration, the pharmacokinetic parameters at 30 mg/kg/d were not significantly different than those at 10 mg/kg/d; however, parameters at 90 mg/kg/d were significantly different than those at 10 mg/kg/d. These data suggest that the pharmacokinetic parameters of DW-224a are dose independent after a single oral administration. After 4 weeks (on the 28th day) of oral administration, the dose-normalized AUC 0-24 h values at 30 (115% increase) and 90 (8.3% decrease) mg/kg/d were not significantly greater than those at 10 mg/kg/d, which suggests that DW-224a is not accumulated after 4-week oral administration. This was also observed when the dose-normalized AUC 0-24 h and C max values were compared with those after single administration. For example, the pharmacokinetic parameters of DW-224a listed in Table 7 were not significantly different between single and 4-week oral administration at all doses. The most common ad- 838 Vol. 26, No. 6 verse effects associated with the fluoroquinolones are GI effects such as nausea, vomiting, and diarrhea. In our experiment, DW-224a was found to cause vomiting and might change the physiological condition of the GI tract, and therefore T max at 90 mg/kg/d was delayed compared with that of a single administration (0.833 to 3.00 h). This was also observed at 30 mg/kg/d, which caused moderate vomiting. Therefore we concluded from the above data that DW-224a is not accumulated above the toxic dose, 30 mg/kg/d, after 4-week oral administration. 
